197 related articles for article (PubMed ID: 24789002)
1. Tuberculosis reactivation risk in dermatology.
Pescitelli L; Ricceri F; Prignano F
J Rheumatol Suppl; 2014 May; 91():65-70. PubMed ID: 24789002
[TBL] [Abstract][Full Text] [Related]
2. Guidance for the management of patients with latent tuberculosis infection requiring biologic therapy in rheumatology and dermatology clinical practice.
Cantini F; Nannini C; Niccoli L; Iannone F; Delogu G; Garlaschi G; Sanduzzi A; Matucci A; Prignano F; Conversano M; Goletti D;
Autoimmun Rev; 2015 Jun; 14(6):503-9. PubMed ID: 25617816
[TBL] [Abstract][Full Text] [Related]
3. Risk of tuberculosis in patients with chronic immune-mediated inflammatory diseases treated with biologics and tofacitinib: a systematic review and meta-analysis of randomized controlled trials and long-term extension studies.
Souto A; Maneiro JR; Salgado E; Carmona L; Gomez-Reino JJ
Rheumatology (Oxford); 2014 Oct; 53(10):1872-85. PubMed ID: 24821849
[TBL] [Abstract][Full Text] [Related]
4. Risk of tuberculosis reactivation associated with traditional disease modifying anti-rheumatic drugs and non-anti-tumor necrosis factor biologics in patients with rheumatic disorders and suggestion for clinical practice.
Cantini F; Niccoli L; Capone A; Petrone L; Goletti D
Expert Opin Drug Saf; 2019 May; 18(5):415-425. PubMed ID: 31066297
[TBL] [Abstract][Full Text] [Related]
5. Restarting biologics and management of patients with flares of inflammatory rheumatic disorders or psoriasis during active tuberculosis treatment.
Cantini F; Prignano F; Goletti D
J Rheumatol Suppl; 2014 May; 91():78-82. PubMed ID: 24789004
[TBL] [Abstract][Full Text] [Related]
6. Diagnosis of latent tuberculosis and prevention of reactivation in rheumatic patients receiving biologic therapy: international recommendations.
Iannone F; Cantini F; Lapadula G
J Rheumatol Suppl; 2014 May; 91():41-6. PubMed ID: 24788999
[TBL] [Abstract][Full Text] [Related]
7. Characteristics Predicting Tuberculosis Risk under Tumor Necrosis Factor-α Inhibitors: Report from a Large Multicenter Cohort with High Background Prevalence.
Kisacik B; Pamuk ON; Onat AM; Erer SB; Hatemi G; Ozguler Y; Pehlivan Y; Kilic L; Ertenli I; Can M; Direskeneli H; Keser G; Oksel F; Dalkilic E; Yilmaz S; Pay S; Balkarli A; Cobankara V; Cetin GY; Sayarlioglu M; Cefle A; Yazici A; Avci AB; Terzioglu E; Ozbek S; Akar S; Gul A
J Rheumatol; 2016 Mar; 43(3):524-9. PubMed ID: 26773107
[TBL] [Abstract][Full Text] [Related]
8. Effectiveness of recommendations to prevent reactivation of latent tuberculosis infection in patients treated with tumor necrosis factor antagonists.
Carmona L; Gómez-Reino JJ; Rodríguez-Valverde V; Montero D; Pascual-Gómez E; Mola EM; Carreño L; Figueroa M;
Arthritis Rheum; 2005 Jun; 52(6):1766-72. PubMed ID: 15934089
[TBL] [Abstract][Full Text] [Related]
9. National Psoriasis Foundation consensus statement on screening for latent tuberculosis infection in patients with psoriasis treated with systemic and biologic agents.
Doherty SD; Van Voorhees A; Lebwohl MG; Korman NJ; Young MS; Hsu S; National Psoriasis Foundation
J Am Acad Dermatol; 2008 Aug; 59(2):209-17. PubMed ID: 18485527
[TBL] [Abstract][Full Text] [Related]
10. [Biologics and mycobacterial diseases].
Tsuyuguchi K; Matsumoto T
Kekkaku; 2013 Mar; 88(3):337-53. PubMed ID: 23672175
[TBL] [Abstract][Full Text] [Related]
11. The spectrum of tuberculosis infection: new perspectives in the era of biologics.
Delogu G; Goletti D
J Rheumatol Suppl; 2014 May; 91():11-6. PubMed ID: 24788995
[TBL] [Abstract][Full Text] [Related]
12. Performance of the tuberculin skin test and interferon-γ release assays: an update on the accuracy, cutoff stratification, and new potential immune-based approaches.
Goletti D; Sanduzzi A; Delogu G
J Rheumatol Suppl; 2014 May; 91():24-31. PubMed ID: 24788997
[TBL] [Abstract][Full Text] [Related]
13. Tuberculosis in biologic users for rheumatic diseases: results from the South African Biologics Registry (SABIO).
Pettipher C; Benitha R
Ann Rheum Dis; 2020 Feb; 79(2):292-299. PubMed ID: 31791950
[TBL] [Abstract][Full Text] [Related]
14. Preventive therapy for tuberculosis in rheumatological patients undergoing therapy with biological drugs.
Goletti D; Petrone L; Ippolito G; Niccoli L; Nannini C; Cantini F
Expert Rev Anti Infect Ther; 2018 Jun; 16(6):501-512. PubMed ID: 29848120
[TBL] [Abstract][Full Text] [Related]
15. Interferon-γ release assay for tuberculosis in patients with psoriasis treated with tumour necrosis factor antagonists: in vivo and in vitro analysis.
Sauzullo I; Mengoni F; Marocco R; Potenza C; Skroza N; Tieghi T; Lichtner M; Vullo V; Mastroianni CM
Br J Dermatol; 2013 Nov; 169(5):1133-40. PubMed ID: 23909256
[TBL] [Abstract][Full Text] [Related]
16. Is 'class effect' relevant when assessing the benefit/risk profile of a biologic agent?
Sterry W; van de Kerkhof P
J Eur Acad Dermatol Venereol; 2012 Aug; 26 Suppl 5():9-16. PubMed ID: 22758912
[TBL] [Abstract][Full Text] [Related]
17. New therapies versus first-generation biologic drugs in psoriasis: a review of adverse events and their management.
Carrascosa JM; Del-Alcazar E
Expert Rev Clin Immunol; 2018 Apr; 14(4):259-273. PubMed ID: 29557200
[TBL] [Abstract][Full Text] [Related]
18. Review article: minimizing tuberculosis during anti-tumour necrosis factor-alpha treatment of inflammatory bowel disease.
Theis VS; Rhodes JM
Aliment Pharmacol Ther; 2008 Jan; 27(1):19-30. PubMed ID: 17944997
[TBL] [Abstract][Full Text] [Related]
19. QuantiFERON TB-gold conversion rate among psoriasis patients under biologics: a 9-year retrospective study.
Megna M; Ferrillo M; Ruggiero A; Cinelli E; Gallo L; Fabbrocini G
Int J Dermatol; 2021 Mar; 60(3):352-357. PubMed ID: 32989759
[TBL] [Abstract][Full Text] [Related]
20. Detection and management of latent tuberculosis infections before biologic therapy for psoriasis.
Amerio P; Amoruso G; Bardazzi F; Campanati A; Cassano N; Conti A; Gisondi P; Guarneri C; Mazzotta A; Piaserico S; Prestinari F; Prignano F; Zane C; de Simone C
J Dermatolog Treat; 2013 Aug; 24(4):305-11. PubMed ID: 22208431
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
